DE69925567D1 - Gene-delivery vectors with tissue tropism for smooth muscle cells and / or endothelial cells - Google Patents

Gene-delivery vectors with tissue tropism for smooth muscle cells and / or endothelial cells

Info

Publication number
DE69925567D1
DE69925567D1 DE69925567T DE69925567T DE69925567D1 DE 69925567 D1 DE69925567 D1 DE 69925567D1 DE 69925567 T DE69925567 T DE 69925567T DE 69925567 T DE69925567 T DE 69925567T DE 69925567 D1 DE69925567 D1 DE 69925567D1
Authority
DE
Germany
Prior art keywords
tissue tropism
smooth muscle
adenovirus
gene
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69925567T
Other languages
German (de)
Other versions
DE69925567T2 (en
Inventor
Menzo Jans Emco Havenga
Ronald Vogels
Abraham Bout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Application granted granted Critical
Publication of DE69925567D1 publication Critical patent/DE69925567D1/en
Publication of DE69925567T2 publication Critical patent/DE69925567T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Abstract

The invention provides a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism for smooth muscle cells and/or endothelial cells. In one aspect said nucleic acid delivery vehicle is a virus capsid or a functional part, derivative and/or analogue thereof. Preferably said virus capsid is an adnovirus capsid. Preferably said adenovirus is a subgroup B adenovirus, preferably adenovirus 16. Preferably said tissue tropism is provided by at least a tissue tropism determining part of an adenovirus fiber protein or a functional derivative and/or analogue thereof. The invention further presents methods for the treatment of diseases, preferably cardiovascular diseases.
DE69925567T 1998-11-20 1999-11-19 Gene-delivery vectors with tissue tropism for smooth muscle cells and / or endothelial cells Expired - Lifetime DE69925567T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203921 1998-11-20
EP98203921 1998-11-20

Publications (2)

Publication Number Publication Date
DE69925567D1 true DE69925567D1 (en) 2005-07-07
DE69925567T2 DE69925567T2 (en) 2006-05-04

Family

ID=8234363

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69925567T Expired - Lifetime DE69925567T2 (en) 1998-11-20 1999-11-19 Gene-delivery vectors with tissue tropism for smooth muscle cells and / or endothelial cells

Country Status (12)

Country Link
JP (1) JP4683682B2 (en)
AT (1) ATE296894T1 (en)
AU (1) AU770780B2 (en)
CA (1) CA2318492C (en)
DE (1) DE69925567T2 (en)
ES (1) ES2244145T3 (en)
IL (1) IL133032A (en)
MX (1) MXPA99010682A (en)
NO (1) NO995697L (en)
NZ (1) NZ501214A (en)
WO (1) WO2000031285A1 (en)
ZA (1) ZA997213B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1159438B1 (en) * 1999-03-04 2008-07-30 Crucell Holland B.V. Use of adenoviral vector for synovial cell transduction
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
JP2003534805A (en) 2000-05-31 2003-11-25 ユニバーシティ オブ サスカチュワン Modified bovine adenovirus with altered affinity
EP1322774A2 (en) * 2000-09-20 2003-07-02 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for dendritic cells
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
EP1482052A1 (en) * 2003-05-27 2004-12-01 Cytos Biotechnology AG Modified polypeptides for targeting cell-entry of the adenoviruses of subtype B
JP7216668B2 (en) 2017-05-26 2023-02-01 エピセントアールエックス，インコーポレイテッド Recombinant adenovirus carrying the transgene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
AU731767B2 (en) * 1995-06-15 2001-04-05 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL124654A0 (en) * 1995-11-28 1998-12-06 Genvec Inc Vectors and method for gene transfer to cells
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
FR2758822B1 (en) * 1997-01-30 1999-07-02 Centre Nat Rech Scient USE OF A POLYPEPTIDE AS A CELLULAR RECEPTOR OF ADENOVIRUS
FR2761689B1 (en) * 1997-04-02 1999-06-25 Transgene Sa MODIFIED ADENOVIRAL FIBER AND TARGET ADENOVIRUS

Also Published As

Publication number Publication date
ZA997213B (en) 2000-05-22
IL133032A (en) 2007-06-03
CA2318492A1 (en) 2000-06-02
CA2318492C (en) 2010-05-11
NO995697D0 (en) 1999-11-19
DE69925567T2 (en) 2006-05-04
NZ501214A (en) 2002-02-01
WO2000031285A1 (en) 2000-06-02
AU770780B2 (en) 2004-03-04
JP4683682B2 (en) 2011-05-18
NO995697L (en) 2000-05-22
IL133032A0 (en) 2001-03-19
ATE296894T1 (en) 2005-06-15
JP2000157289A (en) 2000-06-13
ES2244145T3 (en) 2005-12-01
MXPA99010682A (en) 2002-03-08
AU5960099A (en) 2000-05-25

Similar Documents

Publication Publication Date Title
ATE403006T1 (en) USE OF AN ADENOVIRUS VECTOR FOR TRANSDUCING SYNOVIAL CELLS
DE59913833D1 (en) STRUCTURAL PROTEIN OF AAV, ITS MANUFACTURE AND USE
DE69841982D1 (en) COMPOSITIONS FOR USE IN GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA
ES2156958T3 (en) ADENOVIRUS-AAV HYBRID VIRUS AND SAME USE METHOD.
ATE231549T1 (en) METHOD FOR PRESERVING INFECTIOUS RECOMBINING VIRUSES, VIRAL AQUEOUS SUSPENSION AND MEDICAL USE THEREOF
DE60323078D1 (en) IMPROVED RAAV EXPRESSION SYSTEMS FOR THE GENETIC MODIFICATION OF SPECIFIC CAPSID PROTEINS
EA199900262A1 (en) ANGIOGENIC FACTOR AND METHOD OF ITS APPLICATION IN THE TREATMENT OF CARDIOVASCULAR DISEASE
DE69922933D1 (en) APPLICATIONS FOR HUMAN NON AUTOLOGOLOGY, MESENCHYMAL STEM CELLS
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
DE69925567D1 (en) Gene-delivery vectors with tissue tropism for smooth muscle cells and / or endothelial cells
DE69516416D1 (en) DETERMINING THE INTERACTION POINT BETWEEN P21-WAF AND PCNA AND THEIR THERAPEUTIC USE
ATE363070T1 (en) EVALUATION OF BIOLOGICAL AGENTS IN LIVING TARGET CELLS
ATE234862T1 (en) GLYCOPROTEINS WITH LIPID MOBILIZING PROPERTIES AND THEIR THERAPEUTIC USES
ATE214708T1 (en) CATIONIC AGENTS FOR TRANSFECTION OF NUCLEIC ACIDS
ATE331794T1 (en) HUMAN PROSTACYCLIN SYNTHASE
WO1999031136A3 (en) Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
ATE428793T1 (en) ADENOVIRAL VECTORS FOR TRANSFER OF GENES INTO SKELETON MUSCLE CELLS OR MYOBLASTS
ATE407944T1 (en) PROTEIN MTR1 RELATED TO TRP PROTEINS AND DNA CODING SEQUENCE THEREOF
FR2756491B1 (en) TRANSFECTING COMPOSITION USEFUL IN GENE THERAPY ASSOCIATED WITH A RECOMBINANT VIRUS INCORPORATING EXOG ENE NUCLEIC ACID, A NON-VIRAL AND NON-PLASMIDIC TRANSFECTING AGENT
AU3083500A (en) Use of apoptosis inducing agents in the treatment of (auto)immune diseases
DE69829174D1 (en) EXPRESSION OF A MODIFIED "FOAMY VIRUS ENVELOPE PROTEIN" (SLEEP PROTEIN)
TR199900555T2 (en) Use of protein as an inhibitor of virus relocation to the body.
MX9703191A (en) Antibodies against allogenic and xenogenic proteins, their use in diagnosis and therapy and methods for the determination thereof
BR9713329A (en) Resistance mediated by the coating protein in plants

Legal Events

Date Code Title Description
8364 No opposition during term of opposition